CORE--MINIMAL DISEASE DETECTION BY FISH

核心——鱼类微小疾病检测

• 批准号: 6203154
• 负责人: MICHAEL J SICILIANO
• 金额: $ 7.93万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-12 至 2000-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6203154
• 关键词: biomedical facility; chromosome translocation; chronic myelogenous leukemia; cytogenetics; fluorescent in situ hybridization; human therapy evaluation; human tissue; minimal residual disease; phenotype

We have developed a fluorescent in situ hybridization (FISH) technique for identification of the Ph chromosome in hundreds of cycling cells of the marrow in diagnosis, during, and after therapy. Since so many metaphases are exposed to such analysis the method has been named hypermetaphase FISH or HMF. The procedure enables the determination of statistically significant differences (,4%) in the frequency of Ph+ cells present in patients at presentation and also the detection of minimal levels of such cells (<1%) in patients during treatment. Data to support those contentions are presented. We will employ this procedure to: 1. Determine the frequency of Ph+ cells at presentation and the relationship between that frequency to clinical outcome. 2. Determine the frequency of Ph+ cells during treatment and/or at time points post-BMT in patients with minimal residual disease (MRD) and determine the clinical significance of statistically significant levels and differences. The Core will provide a service to the clinical projects (Projects 1, 2, and 3 involving Drs. Kantarjian, Talpaz, Champlin, and Claxton). Results will also be correlated with the quantitative RT/PCR and bcr/abl results of Dr. Arlinghaus' Core (Core D) to determine the relative benefits and shortcomings of each of the technologies in establishing the cytogenetic response to therapies involved. This information will be cycled back to the clinical projects of the Program to permit the selection of patient care algorithms of individuals for specific types of therapy. These procedures will give us new insights into determining the clinically significant levels of minimal residual disease and guide the further management of individual malignancies in CML patients.

我们开发了一种荧光原位杂交(FISH)技术 中华绒毛虫成百上千个细胞中Ph染色体的鉴定 骨髓在诊断中、治疗中和治疗后。因为有这么多的隐喻 都暴露在这样的分析中，这种方法被称为超中期FISH 或者是HMF。该程序能够在统计上确定 存在显著差异(4%)的Ph+细胞出现在 患者的表现以及对这种最低水平的检测 治疗过程中患者体内的细胞(1%)。数据来支持这些 文中提出了一些论点。我们将使用此程序来： 1.测定Ph+细胞在分娩时的频率和 这种频率与临床结果之间的关系。 2.在治疗过程中和/或在一定时间测定Ph+细胞频率 微小残留病(MRD)患者骨髓移植后积分 确定统计学显著水平的临床意义 和差异。 中心将为临床项目(项目1、2、 涉及坎塔尔健、塔尔帕兹、钱普林和克莱克斯顿博士的3例)。结果 也将与定量RT/PCR和BCR/ABL结果相关 阿林豪斯博士的核心(核心D)，以确定相对益处和 每种技术在建立细胞遗传学研究中的不足 对所涉及的治疗的反应。 这些信息将被循环返回到 允许选择个人的患者护理算法的程序 用于特定类型的治疗。这些程序将给我们带来新的见解 确定临床上有意义的最小残留量水平 指导慢性粒细胞白血病的个体化治疗 病人。